Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Mr. Mack is the Company's Current CFO "On behalf of Gain, I would like to thank Matthias for his significant contribution to the development of our company, as we advanced our lead candidate, GT-02287, into clinical development. Matthias played an instrumental role building the preclinical dossier for GT-02287 including the most recent positive data presented this week at FENS Forum 2024, in which administration of GT-02287 was associated with significant improvement in cognitive performance and other relat ...